Kids' CF drug levels under the microscope
NCT ID NCT07303621
First seen Jan 04, 2026 · Last updated May 10, 2026 · Updated 16 times
Summary
This study looks at how the cystic fibrosis drug elexacaftor-tezacaftor-ivacaftor behaves in children aged 2 to 17. Researchers want to understand how drug levels in the blood relate to benefits and side effects. About 150 children with cystic fibrosis who already take this medication will provide blood samples and health data. The goal is to improve dosing and reduce risks like liver or mood problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS (CF) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hôpital Femme Mère Enfant (HFME)
RECRUITINGBron, 69029, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.